Association of hypertension defined by the 2017 ACC/AHA guideline and choroidal thickness changes in type 2 diabetes: a 2-year longitudinal study.

Purpose: This prospective cohort study investigated the longitudinal relationship between hypertension (HTN), defined by the 2017 ACC/AHA guidelines, and changes in choroidal thickness (CT) in patients with type 2 diabetes.

Methods: Patients aged 30-80 years from the Guangzhou Diabetic Eye Study were categorized into non-HTN, stage 1-HTN, and stage 2-HTN groups based on BP criteria. Macular and parapapillary CT were measured using swept-source optical coherence tomography (SS-OCT). Mixed linear regression models analysed CT decline rates over a median 2.1-year follow-up, adjusting for confounders.

Results: 803 diabetes patients were included. Both stage 1-HTN and stage 2-HTN groups showed significantly thinner macular and parapapillary CT compared to non-HTN (all P < 0.05). Stage 2-HTN correlated with reduced macular CT thinning (coef = -11.29 μm/year; 95% CI, -22.36 to -0.22; P = 0.046) after adjustment, but not in the parapapillary area (coef = -4.07 μm/year; 95% CI, -12.89 to 4.74; P = 0.365). Subgroup analyses indicated faster macular CT decline in stage 2-HTN among those <65 years old (coef = -20.31 μm/year; 95% CI, -35.67 to -4.95; P = 0.10), males (coef = -14.1 μm/year; 95% CI, -32.54 to -4.33; P = 0.004), BMI ≥ 25 kg/m (coef = -10.24 μm/year; 95% CI, -26.86 to -6.38; P = 0.007), HbA1c > 6.5% (coef = -8.91 μm/year; 95% CI, -13.49 to -4.68; P = 0.001), and diabetes duration <10 years (coef = -12.78 μm/year; 95% CI, -27.48 to -1.91; P = 0.008).

Conclusion: Stage 2-HTN is associated with accelerated macular CT loss in diabetic patients, suggesting macular CT measurements could potentially serve as early indicators of systemic hypertension. Further research is needed to establish precise CT cutoff values for clinical use in detecting and monitoring hypertension-related ocular changes.